Today, Aurinia Pharmaceuticals Inc. (AUPH) Rating Reiterate by HC Wainwright

Today, Aurinia Pharmaceuticals Inc. (AUPH) Rating Reiterate by HC Wainwright
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. They presently have a $10.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 215.46% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 5th. FBR & Co reissued an “outperform” rating and issued a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, November 4th. Leerink Swann reissued an “outperform” rating and issued a $7.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Monday, October 3rd. Finally, Mackie reissued a “buy” rating and issued a $8.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 2nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and an average target price of $7.79.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 3.17 on Tuesday. The firm has a 50-day moving average of $3.51 and a 200 day moving average of $2.92. The company’s market capitalization is $125.93 million. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $5.69.

A number of institutional investors have recently bought and sold shares of AUPH. Abingworth LLP boosted its position in Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock valued at $1,388,000 after buying an additional 423,729 shares during the last quarter. Lombard Odier Asset Management USA Corp boosted its position in Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares during the last quarter. Creative Planning bought a new position in Aurinia Pharmaceuticals during the third quarter valued at $181,000. SG Americas Securities LLC bought a new position in Aurinia Pharmaceuticals during the third quarter valued at $1,123,000. Finally, KCG Holdings Inc. bought a new position in Aurinia Pharmaceuticals during the third quarter valued at $153,000. 19.06% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Related posts

Leave a Comment